July 22, 2025 7:50am

I usually write/say “electronic trading and uncle algo” slips in and out, back doors delivering sector harmony and then pops right back for some profiteering. Algos and electronic trading, can’t do with them and can’t do without them!

Pre-open Signals: 2 Negative and 4 Sell into Strength Indications

Earnings are a’comin: 7/29, Tuesday = uniQure NV (QURE), 7/30, Wednesday = MiMedx (MDXG), 7/31, Thursday = Alnylam Pharmaceuticals (ALNY), Vericel (VCERL), 8/1 = Ionis Pharmaceuticals (IONS) and Moderna (MRNA)

Never leave an investor uninformed …

I say what others won’t, so you can do what others can’t!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Let’s get to the point, few adverbs and even fewer adjectives, no vacillating; I get right to the point, telling investors what has meaning and why news or indications matter.

 

Monday’s night’s … RegMed Investors (RMi) Closing Bell:  flipping share pricing burgers on high … https://www.regmedinvestors.com/articles/14006

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Sustaining a Loser … https://www.regmedinvestors.com/articles/13812

 

Tuesday: The pre-open Dow futures are DOWN -0.20% or (-87 points), the S&P futures are DOWN -0.11% or (-7 points) and the Nasdaq futures are DOWN -0.17% or (-39 point)

  • U.S. stock futures were “flitting” lower on Tuesday, 7/22
  • European were “streaming” lower again, 
  • Asia-Pacific markets closed mixed 

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Monday: The Dow closed DOWN -19.12 points or -0.04%, the S&P closed UP +8.81 points or +0.14% while the Nasdaq closed UP +78.52 points or +0.38%
  • Friday: The Dow closed DOWN -142.30 points or -0.323%, the S&P closed DOWN -0.547 points or -0.01% while the Nasdaq closed UP +10.01 points or +0.05%
  • Last week, the S&P 500 gained +0.06%, the Dow fell 1% and the Nasdaq popped +1.5%.

Economic Data Docket: traders will be monitoring Fed Chair Powell’s comments at an event in Washington

 

Q3 – July – 1 market holiday, 10 positive and 3 negative closes

Q2  

  • June – 1 market holiday, 1 neutral, 8 negative, and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 10 negative and 11 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • It is still a mix of ups, downs and just uncertainty …

Although from my usual suspects:

Alnylam Pharmaceuticals (ALNY) closed down -$0.01 after Friday’s -$4.16 with a negative -$3.00 or -0.94% pre-open

Mesoblast (MESO) closed down -$0.97 after Friday’s +$3.28 with a negative -$0.45 or -3.07% pre-open

Beam Therapeutics (BEAM) closed up +$0.28 after Friday’s +$0.30 after Thursday’s +$0.38, Wednesday’s +$0.51 and last Tuesday’s -$1.59 with a positive +$0.07 or +0.33% pre-open – Sell into Strength

CRISPR Therapeutics (CRSP) closed up +$0.20 after Friday’s +10.10.04, Thursday’s -$0.05, Wednesday’s +$2.48 and last Tuesday’s -$3.69 with a positive +$0.22 or +0.34% pre-open – Sell into Strength

Moderna (MRNA) closed down -$0.29 after Friday’s -$0.94, Thursday’s +$0.14, Wednesday’s +$0.52 and last Tuesday’s -$1.29 with a positive +$0.03 or +0.12% pre-open – Sell into Strength

Intellia Therapeutics (NTLA) closed up +$0.57 after Friday’s +$0.22, Thursday’s -0.13 and last Wednesday’s +0.53 with a positive +0.07 or +0.55% pre-open – Sell into Strength

 

The BOTTOM LINE: I believe … RED flags are flying and the firing range is open!

Futures edged lower on Tuesday as investors braced for a busy day of earnings while navigating uncertainties around U.S. trade negotiations with key partners

  • The cautious moves follow a volatile session on Monday, when the S&P 500 and the Nasdaq climbed to record closing highs on strength in mega caps ahead of its quarterly results.
  • Negotiations appeared to remain deadlocked as the European Union explores a wider array of possible countermeasures against the U.S. Meanwhile, prospects of an interim trade deal between India and the United States have dimmed, Indian government sources.
  • U.S. Federal Reserve Chair Powell's speech at 8:30 a.m. ET will be closely watched for clues about the central bank's next policy move.
  • After a slew of mixed economic data last week, traders have ruled out the possibility of an interest-rate cut next week and see a 56.3% chance of a reduction in September, according to the CME FedWatch tool. <Reuters>

July is slowly coming to an end with 8 sessions left.

  • After econs stifled the sector and markets, and summer doldrums, tariff conflicts, vacations and selling before the earnings cycle to pay for the lobster rolls.

Cell and gene therapy sector equities closed Monday positive after Friday’s negative after positive Thursday and Wednesday continued the run to the upside after Tuesday positive close after diving on Monday

  • After last week popping multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

To characterize July, to understand the “flow” of markets, the cell and gene therapy sector and economic karma…

  • 7/21 – Monday closed positive with 17 positive, 14 negative and 4 flats

Last week:

  • 7/18 – Friday closed negative with 10 positive, 21 negative and 4 flats
  • 7/17 – Thursday closed positive with 17 positive, 14 negative and 4 flats
  • 7/16 - Wednesday closed positive with 24 positive, 5 negative and 6 flats
  • 7/15 - Tuesday closed negative with 3 positive, 29 negative and 3 flats
  • 7/14 - Monday closed positive with 20 positive, 11 negative and 4 flats

The previous week:

  • 7/11 – Friday closed negative with 5 positive, 28 negative and 2 flats
  • 7/10 – Thursday closed positive with 19 positive, 14 negative and 2 flats
  • 7/9 – Wednesday closed positive with 28 positive, 5 negative and 2 flats
  • 7/8 - Tuesday closed positive with 22 positive, 10 negative and 3 flats
  • 7/7 – Monday closed negative with 6 positive, 27 negative and 2 flats

 

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

  • Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

As always, I brace myself for more volatility, economics and their down trending affect?

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

 I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.